Can we turn off the “Covid-biting-tail” inflammation?

Valentina Giudice  
Hematology and Transplant Center, University Hospital “San Giovanni di Dio e Ruggi d’Aragona”, Italy, vgiudice@unisa.it

Amelia Filippelli  
Department of Medicine, Surgery and Dentistry “Scuola Medica Salernitana”, University of Salerno, Italy, afilippelli@unisa.it

Carmine Selleri  
1Department of Medicine, Surgery and Dentistry “Scuola Medica Salernitana”, University of Salerno, Italy, cselleri@unisa.it

Follow this and additional works at: https://tmj.unisa.it/journal

Part of the Chemicals and Drugs Commons

**Recommended Citation**  
Giudice, Valentina; Filippelli, Amelia; and Selleri, Carmine (2020) "Can we turn off the “Covid-biting-tail” inflammation?,” *Translational Medicine @ UniSa*: Vol. 23 : Iss. 4 , Article 5.  
Available at: https://doi.org/10.37825/2239-9747.1006

This Article is brought to you for free and open access by Translational Medicine @ UniSa. It has been accepted for inclusion in Translational Medicine @ UniSa by an authorized editor of Translational Medicine @ UniSa.
Can we turn off the “Covid-biting-tail” inflammation?

Giudice Valentina1,2,3, Filippelli Amelia1,2, Selleri Carmine1,3
1Department of Medicine, Surgery and Dentistry “Scuola Medica Salernitana”, University of Salerno, Italy.
2Clinical Pharmacology, University Hospital “San Giovanni di Dio e Ruggi d’Aragona”, Italy.
3Hematology and Transplant Center, University Hospital “San Giovanni di Dio e Ruggi d’Aragona”, Italy.

(vgiudice@unisa.it)

Keywords: SARS-CoV-2, Covid-19, inflammation

Dear Editor,

More than 30% of subjects with Covid-19 requires intensive care unit admission, and in several cases, patients develop severe respiratory symptoms and an acute respiratory distress syndrome (ARDS) requiring intensive care treatment, and precipitating factors are still under investigation; however, a massive release of pro-inflammatory cytokines and chemokines from immune cells is one of the main pathogenetic mechanisms. Based on previous findings in SARS-CoV and Middle East respiratory syndrome CoV diseases, infected macrophages can belatedly release high amount of pro-inflammatory cytokines, especially TNFα and IL-6, and sustain and enhance inflammatory and immune responses during SARS-CoV-2 infection contributing to ARDS development and subsequently to the multiorgan failure syndrome (MOFS) [1].

The main viral entry mechanism is the binding of the viral “Spike” protein to the surface Angiotensin-Converting Enzyme 2 (ACE-2) receptor on host alveolar epithelial cells. ACE-2, a zinc containing type I transmembrane metalloenzyme, regulates blood pressure through the renin-angiotensin system (RAS), and is highly expressed on various cell types, such as vascular endothelial cells and alveolar epithelial cells [2]. Therefore, SARS-CoV-2 virus infects alveolar cells through ACE-2 receptor binding sequestering available receptors for RAS regulation and increasing kinin, complement, and coagulation cascade activation. The complement system, a multi-step pathway of the innate immune response, causes the formation of pores on pathogen membranes inducing lysis and enhancing phagocytosis by macrophages, and releases several pro-inflammatory molecules, the anaphylatoxins, that amplify inflammation and immune responses [1-2]. Some of those molecules can trigger the activation of kinin and coagulation cascades which can sustain vascular permeability and thrombosis also occurring during ARDS. In addition, vascular permeability facilitates neutrophil and macrophage recruitment at the site of viral infection supporting inflammation and tissue damage. Simultaneously, infected cells trigger adaptive immune responses, such as Th1 with release of type I interferons, macrophage recruitment and activation with release of IL-1 and TNFα. These mechanisms might increase vascular permeability and neutrophil recruitment in the site of viral infection with production of large amount of pro-inflammatory cytokines, especially IL-6, and anaphylatoxins which sustain inflammation and tissue damage as in a “dog-biting-tail” system until pulmonary edema, thrombosis and respiratory distress develop and progress to ARDS and MOFS (Figure 1).

Currently, there are no specific therapies for Covid-19; however, a lot of available drugs used in other diseases, especially autoimmune disorders, are under investigation for treatment of severe SARS-CoV-2 infection or for prophylaxis [3]. In particular, eculizumab, an anti-C5a complement factor monoclonal antibody used for treatment of paroxysmal nocturnal hemoglobinuria, is currently under investigation in the United States (SOLID-C19 trial NCT04288713) and Italy for treatment of Covid-19. Growing evidence of efficacy of eculizumab in SARS-CoV-2-related ARDS are accumulating showing a potential benefit of this drug in reducing platelet consumption and intravascular coagulation thus preventing thrombosis of pulmonary capillaries and interstitial pneumonia or reducing ongoing pulmonary lesions [4]. In addition, Janus kinase (JAK) inhibitors are under investigation because of the wide involvement of JAK/STAT pathway in transducing the signals of several cytokine stimulation, such as interferons and TNFα [3]. In 2019, the Food and Drug Administration has approved ruxolitinib, a JAK1/2 inhibitor, for treatment of Graft-versus-Host disease (GvHD) because ruxolitinib has shown in vitro and in vivo efficacy in modulating immune responses, especially those exerted by Natural Killer cells, DCs, Th1 and Th17 cells, and regulatory T lymphocytes, and in regulating release of several cytokines including TNFα. Moreover, ruxolitinib can reduce viral replication, as already described for HIV in vitro and mouse models. Preliminary results have described a fast clinical recovery of Covid-19 patients treated with ruxolitinib compared to placebo; however, JAK inhibition might cause severe adverse events, including cutaneous rash.

Based on the hypothesis that SARS-CoV-2 infection triggers a “dog-biting-tail” inflammatory loop, the use of a single anti-inflammatory agent might be not sufficient in severe Covid-19; thus, a combination of drugs
would be advisable in preventing ARDS and MOFS in intensive care patients. For example, we have described clinical improvements of six severe Covid-19 cases treated with ruxolitinib 10 mg/twice daily for 14 days and eculizumab 900 mg IV/weekly for three weeks [5].

Patients treated with the combination showed significant improvements in respiratory symptoms and radiographic pulmonary lesions, and decreased levels of circulating D-dimers while significant increase in platelet counts. Therefore, eculizumab could reduce complement and coagulation cascade activation and decrease vascular permeability and thrombosis on one side; while ruxolitinib might inhibit Th1 and macrophage activation ultimately leading to reduced neutrophil recruitment in the site of viral infection. In conclusion, combined use of anti-inflammatory drugs acting on different but connected pathways during severe Covid-19 might dramatically turn off inflammation in the lungs thus reducing the risk of ARDS and MOFS development.
REFERENCES